JP2013540117A - 腫瘍幹細胞におけるｅｐｈ受容体発現 - Google Patents
腫瘍幹細胞におけるｅｐｈ受容体発現 Download PDFInfo
- Publication number
- JP2013540117A JP2013540117A JP2013530753A JP2013530753A JP2013540117A JP 2013540117 A JP2013540117 A JP 2013540117A JP 2013530753 A JP2013530753 A JP 2013530753A JP 2013530753 A JP2013530753 A JP 2013530753A JP 2013540117 A JP2013540117 A JP 2013540117A
- Authority
- JP
- Japan
- Prior art keywords
- gbm
- epha2
- cells
- csc
- ephrina1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 122
- 230000014509 gene expression Effects 0.000 title claims description 89
- 102000050554 Eph Family Receptors Human genes 0.000 title claims description 55
- 108091008815 Eph receptors Proteins 0.000 title claims description 55
- 210000000130 stem cell Anatomy 0.000 title claims description 46
- 208000005017 glioblastoma Diseases 0.000 claims abstract description 79
- 238000011282 treatment Methods 0.000 claims abstract description 67
- 239000003112 inhibitor Substances 0.000 claims abstract description 64
- 230000012010 growth Effects 0.000 claims abstract description 43
- 201000011510 cancer Diseases 0.000 claims abstract description 41
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims description 72
- 230000004663 cell proliferation Effects 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 8
- 230000003211 malignant effect Effects 0.000 claims description 8
- 230000009401 metastasis Effects 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000000975 bioactive effect Effects 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 abstract description 14
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 230000009036 growth inhibition Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 263
- 108010055196 EphA2 Receptor Proteins 0.000 description 113
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 71
- 241000282414 Homo sapiens Species 0.000 description 65
- 239000003446 ligand Substances 0.000 description 45
- 102000051096 EphA2 Receptor Human genes 0.000 description 44
- 108020003175 receptors Proteins 0.000 description 39
- 102000005962 receptors Human genes 0.000 description 39
- 241000699666 Mus <mouse, genus> Species 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 29
- 241000283707 Capra Species 0.000 description 25
- 238000000338 in vitro Methods 0.000 description 24
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 21
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 21
- 230000026731 phosphorylation Effects 0.000 description 21
- 238000006366 phosphorylation reaction Methods 0.000 description 21
- 238000002054 transplantation Methods 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 19
- 102000012803 ephrin Human genes 0.000 description 19
- 108060002566 ephrin Proteins 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 19
- 238000001262 western blot Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 102000007469 Actins Human genes 0.000 description 16
- 108010085238 Actins Proteins 0.000 description 16
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 238000001000 micrograph Methods 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 108010043945 Ephrin-A1 Proteins 0.000 description 14
- 102100040954 Ephrin-A1 Human genes 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000010166 immunofluorescence Methods 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 230000004614 tumor growth Effects 0.000 description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 12
- 210000001178 neural stem cell Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000005754 cellular signaling Effects 0.000 description 11
- 239000007857 degradation product Substances 0.000 description 11
- 230000000284 resting effect Effects 0.000 description 11
- 206010007269 Carcinogenicity Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 231100000260 carcinogenicity Toxicity 0.000 description 10
- 230000007670 carcinogenicity Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000004807 localization Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 206010018338 Glioma Diseases 0.000 description 9
- 230000003436 cytoskeletal effect Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000001577 neostriatum Anatomy 0.000 description 9
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 8
- 208000032612 Glial tumor Diseases 0.000 description 8
- 108010009711 Phalloidine Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000003364 immunohistochemistry Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000027455 binding Effects 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 238000009643 clonogenic assay Methods 0.000 description 6
- 231100000096 clonogenic assay Toxicity 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 230000007480 spreading Effects 0.000 description 6
- 238000003892 spreading Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- -1 EphA10 Proteins 0.000 description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 5
- 229940124647 MEK inhibitor Drugs 0.000 description 5
- 241000021375 Xenogenes Species 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 4
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 4
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000013000 chemical inhibitor Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000013211 curve analysis Methods 0.000 description 4
- 230000030609 dephosphorylation Effects 0.000 description 4
- 238000006209 dephosphorylation reaction Methods 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000009650 gentamicin protection assay Methods 0.000 description 4
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000007917 intracranial administration Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000013643 reference control Substances 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000005748 tumor development Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 3
- 102100023733 Ephrin-B3 Human genes 0.000 description 3
- 108010044085 Ephrin-B3 Proteins 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 101100451971 Mus musculus Ephx2 gene Proteins 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 108010055191 EphA3 Receptor Proteins 0.000 description 2
- 108010055179 EphA4 Receptor Proteins 0.000 description 2
- 108010055182 EphA5 Receptor Proteins 0.000 description 2
- 108010055153 EphA7 Receptor Proteins 0.000 description 2
- 108010055155 EphA8 Receptor Proteins 0.000 description 2
- 108010055334 EphB2 Receptor Proteins 0.000 description 2
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 2
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 2
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 description 2
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 description 2
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 2
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 2
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 2
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 2
- 102100033919 Ephrin-A2 Human genes 0.000 description 2
- 102100033940 Ephrin-A3 Human genes 0.000 description 2
- 102100033942 Ephrin-A4 Human genes 0.000 description 2
- 108010044099 Ephrin-B1 Proteins 0.000 description 2
- 102100033946 Ephrin-B1 Human genes 0.000 description 2
- 102100023721 Ephrin-B2 Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 101000938354 Homo sapiens Ephrin type-A receptor 1 Proteins 0.000 description 2
- 101000938346 Homo sapiens Ephrin type-A receptor 2 Proteins 0.000 description 2
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 description 2
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 description 2
- 101000925269 Homo sapiens Ephrin-A2 Proteins 0.000 description 2
- 101000925241 Homo sapiens Ephrin-A3 Proteins 0.000 description 2
- 101000925259 Homo sapiens Ephrin-A4 Proteins 0.000 description 2
- 101001049392 Homo sapiens Ephrin-B2 Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FGBAVQUHSKYMTC-UHFFFAOYSA-M LDS 751 dye Chemical compound [O-]Cl(=O)(=O)=O.C1=CC2=CC(N(C)C)=CC=C2[N+](CC)=C1C=CC=CC1=CC=C(N(C)C)C=C1 FGBAVQUHSKYMTC-UHFFFAOYSA-M 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 101150022753 galc gene Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000006662 intracellular pathway Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 230000005959 oncogenic signaling Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 101150069931 Abcg2 gene Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 238000010599 BrdU assay Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100031277 Calcineurin B homologous protein 1 Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 101710205625 Capsid protein p24 Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 description 1
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 description 1
- 102100033941 Ephrin-A5 Human genes 0.000 description 1
- 108010043939 Ephrin-A5 Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 description 1
- 101001055531 Homo sapiens Matrix extracellular phosphoglycoprotein Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100026142 Matrix extracellular phosphoglycoprotein Human genes 0.000 description 1
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000044589 Mitogen-Activated Protein Kinase 1 Human genes 0.000 description 1
- 102000046795 Mitogen-Activated Protein Kinase 3 Human genes 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101710149279 Small delta antigen Proteins 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000030002 adult glioblastoma Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MAHXCOMHJBHBGO-RTKIROINSA-N hematoxin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H](OC)C11C=CC(=O)C(O)=C1OC2 MAHXCOMHJBHBGO-RTKIROINSA-N 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 102000046148 human BMP4 Human genes 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000011663 regulation of signaling Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000000564 temperature-controlled scanning calorimetry Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Marine Sciences & Fisheries (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10185930.4 | 2010-10-01 | ||
| EP10185930A EP2446895A1 (en) | 2010-10-01 | 2010-10-01 | EPH receptor expression in tumor stem cells |
| PCT/EP2011/067114 WO2012042021A1 (en) | 2010-10-01 | 2011-09-30 | Eph receptor expression in tumor stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015200808A Division JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2013540117A true JP2013540117A (ja) | 2013-10-31 |
Family
ID=43856109
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530753A Pending JP2013540117A (ja) | 2010-10-01 | 2011-09-30 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2015200808A Active JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2017192907A Active JP6618968B2 (ja) | 2010-10-01 | 2017-10-02 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2019205190A Pending JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015200808A Active JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2017192907A Active JP6618968B2 (ja) | 2010-10-01 | 2017-10-02 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2019205190A Pending JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9078857B2 (enExample) |
| EP (2) | EP2446895A1 (enExample) |
| JP (4) | JP2013540117A (enExample) |
| KR (2) | KR101719966B1 (enExample) |
| AU (1) | AU2011310109B2 (enExample) |
| CA (1) | CA2813101C (enExample) |
| DK (1) | DK2621513T3 (enExample) |
| ES (1) | ES2616444T3 (enExample) |
| NZ (1) | NZ609594A (enExample) |
| PL (1) | PL2621513T3 (enExample) |
| WO (1) | WO2012042021A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20171143A1 (es) | 2010-12-08 | 2017-08-10 | Stem Centrx Inc | Nuevos moduladores y metodos para su uso |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| EP2733206A1 (en) * | 2012-11-19 | 2014-05-21 | Naroa LLC | Method for the isolation for mammalian stem cells using EphA2 and uses thereof |
| AR098221A1 (es) | 2013-11-04 | 2016-05-18 | Pfizer | Conjugados de anticuerpo anti-efna4-fármaco |
| WO2015168019A2 (en) | 2014-04-30 | 2015-11-05 | Pfizer Inc. | Anti-ptk7 antibody-drug conjugates |
| JP6921755B2 (ja) * | 2014-12-10 | 2021-08-18 | ハイパーステム ソシエテ アノニム | 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物 |
| US10783439B2 (en) * | 2015-05-08 | 2020-09-22 | FlowJo, LLC | Plugin interface and framework for integrating a remote server with sample data analysis software |
| IL289849B2 (en) | 2015-11-10 | 2024-01-01 | Nat Inst Biotechnology Negev Ltd | Means and methods for reducing tumorigenicity of cancer stem cells |
| CN115379845B (zh) * | 2020-03-31 | 2024-10-25 | 学校法人庆应义塾 | 使用了基因组编辑多能干细胞的治疗药 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090123371A1 (en) * | 2006-03-08 | 2009-05-14 | Wake Forest University Health Sciences | Molecular signature of cancer |
| US20100183618A1 (en) * | 2007-08-30 | 2010-07-22 | Daiichi Sankyo Company, Limited | Anti-epha2 antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005037233A2 (en) * | 2003-10-15 | 2005-04-28 | Medimmune, Inc. | Listeria-based epha2 vaccines |
| US20060040325A1 (en) * | 2004-08-16 | 2006-02-23 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
-
2010
- 2010-10-01 EP EP10185930A patent/EP2446895A1/en not_active Withdrawn
-
2011
- 2011-04-18 US US13/089,217 patent/US9078857B2/en active Active
- 2011-09-30 PL PL11778540T patent/PL2621513T3/pl unknown
- 2011-09-30 DK DK11778540.2T patent/DK2621513T3/en active
- 2011-09-30 CA CA2813101A patent/CA2813101C/en active Active
- 2011-09-30 KR KR1020167002577A patent/KR101719966B1/ko active Active
- 2011-09-30 NZ NZ609594A patent/NZ609594A/en unknown
- 2011-09-30 JP JP2013530753A patent/JP2013540117A/ja active Pending
- 2011-09-30 AU AU2011310109A patent/AU2011310109B2/en active Active
- 2011-09-30 KR KR1020137011310A patent/KR20130095286A/ko not_active Ceased
- 2011-09-30 WO PCT/EP2011/067114 patent/WO2012042021A1/en not_active Ceased
- 2011-09-30 EP EP11778540.2A patent/EP2621513B1/en active Active
- 2011-09-30 ES ES11778540.2T patent/ES2616444T3/es active Active
-
2015
- 2015-10-09 JP JP2015200808A patent/JP6523910B2/ja active Active
-
2017
- 2017-10-02 JP JP2017192907A patent/JP6618968B2/ja active Active
-
2019
- 2019-11-13 JP JP2019205190A patent/JP2020037579A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090123371A1 (en) * | 2006-03-08 | 2009-05-14 | Wake Forest University Health Sciences | Molecular signature of cancer |
| US20100183618A1 (en) * | 2007-08-30 | 2010-07-22 | Daiichi Sankyo Company, Limited | Anti-epha2 antibody |
Non-Patent Citations (5)
| Title |
|---|
| JPN6014027355; Ｉｎｔ Ｊ Ｏｎｃｏｌ， ｖｏｌ．３０， ｐ．８６５-８７１ （２００７） * |
| JPN6014027357; Ｍｏｌ Ｃａｎｃｅｒ Ｔｈｅｒ， ｖｏｌ．６， ｎｏ．１２， ｐ．３２０８-３２１８ （２００７） * |
| JPN6014027359; Ｍｏｌ Ｃａｎｃｅｒ Ｒｅｓ， ｖｏｌ．３， ｎｏ．１０， ｐ．５４１-５５１ （２００５） * |
| JPN6014027361; Ｏｎｃｏｇｅｎｅ， ｖｏｌ．２８， ｐ．１７５９-１７６８ （２００９） * |
| JPN6014027363; Ｃａｎｃｅｒ Ｃｅｌｌ， ｖｏｌ．２２， ｐ．７６５-７８０ （２０１２） * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011310109A1 (en) | 2013-05-02 |
| KR101719966B1 (ko) | 2017-03-24 |
| WO2012042021A1 (en) | 2012-04-05 |
| JP6618968B2 (ja) | 2019-12-11 |
| EP2446895A1 (en) | 2012-05-02 |
| US20120083454A1 (en) | 2012-04-05 |
| CA2813101C (en) | 2018-10-30 |
| DK2621513T3 (en) | 2017-03-06 |
| CA2813101A1 (en) | 2012-04-05 |
| JP2018048151A (ja) | 2018-03-29 |
| JP2020037579A (ja) | 2020-03-12 |
| KR20160027106A (ko) | 2016-03-09 |
| PL2621513T3 (pl) | 2017-06-30 |
| NZ609594A (en) | 2015-01-30 |
| ES2616444T3 (es) | 2017-06-13 |
| EP2621513A1 (en) | 2013-08-07 |
| KR20130095286A (ko) | 2013-08-27 |
| JP6523910B2 (ja) | 2019-06-05 |
| AU2011310109B2 (en) | 2014-11-20 |
| US9078857B2 (en) | 2015-07-14 |
| EP2621513B1 (en) | 2016-12-28 |
| JP2016094391A (ja) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6618968B2 (ja) | 腫瘍幹細胞におけるｅｐｈ受容体発現 | |
| US20160199457A1 (en) | Modulation of axon degeneration | |
| CA3083373A1 (en) | Enhancing t-cell function and treating a t-cell dysfunctional disorder with a combination of an lsd inhibitor and a pd1 binding antagonist | |
| SG195557A1 (en) | Modulation of axon degeneration | |
| JP5891068B2 (ja) | Ｌｉｆおよびｂｍｐによる腫瘍性幹細胞の潜在的腫瘍形成能力の抑制 | |
| AU2004275798A1 (en) | VEGE-Cor VEGE-D materials and methods for stimulation of neural stem cells | |
| Karl et al. | Endogenous Gas6 and Ca2+-channel activation modulate phagocytosis by retinal pigment epithelium | |
| US20170202910A1 (en) | Differentiation marker and differentiation control of eye cell | |
| Fang et al. | Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions | |
| Jung et al. | The role of endothelin receptor A during myelination of developing oligodendrocytes | |
| JP2008542385A (ja) | 神経損傷の抑制 | |
| Sheahan | The Impact of Doxorubicin on Active Intestinal Stem Cells and Intestinal Regeneration | |
| KR20240052739A (ko) | 급성 골수성 백혈병 치료를 위한 wnt5a | |
| MONAGHAN-NICHOLS et al. | Expression of Tlx in Both Stem Cells and Transit Amplifying Progenitors Regulates Stem Cell Activation and Differentiation in the Neonatal Lateral Subependymal Zone | |
| Relucio | The Role of Laminin a2 in Oligodendrocyte Development and CNS Myelination | |
| AU2015202365A1 (en) | Modulation of axon degeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140701 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140930 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141007 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141030 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141128 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141224 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150609 |